Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery
Version 3 2024-06-20, 01:11
Version 2 2024-06-03, 06:57
Version 1 2017-01-01, 00:00
journal contribution
posted on 2024-06-20, 01:11 authored by D Xiang, Sarah ShigdarSarah Shigdar, AG Bean, M Bruce, Wenrong YangWenrong Yang, Motilal Mathesh ShanmugamMotilal Mathesh Shanmugam, T Wang, W Yin, PHL Tran, HA Shamaileh, RA Barrero, PZ Zhang, Y Li, Lingxue KongLingxue Kong, K Liu, SF Zhou, Y Hou, A He, Wei DuanWei DuanTransforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery
History
Related Materials
- 1.
Location
AustraliaOpen access
- Yes
Language
EnglishPublication classification
C Journal article, C1 Refereed article in a scholarly journalCopyright notice
2017, Ivyspring International PublisherJournal
TheranosticsVolume
7Pagination
4071-4086ISSN
1838-7640eISSN
1838-7640Issue
17Publisher
IVYSPRING INT PUBLUsage metrics
Keywords
Science & TechnologyLife Sciences & BiomedicineMedicine, Research & ExperimentalResearch & Experimental Medicinedoxorubicincancer stem cell killerMOLECULARLY TARGETED AGENTSDOSE-LIMITING TOXICITYMULTIDRUG-RESISTANCEDRUG-DELIVERYADENOCARCINOMANANOPARTICLESTHERAPEUTICSTUMORSMARKERHYDROCHLORIDE111201 Cancer Cell Biology3211 Oncology and carcinogenesis3206 Medical biotechnology
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC